News
2d
MedPage Today on MSNDurable Survival Outcomes in Advanced Melanoma With Neoadjuvant Dual ImmunotherapyParticipants received 480 mg of nivolumab and 160 mg of relatlimab intravenously once every 4 weeks for two cycles before ...
12d
Clinical Trials Arena on MSNChina’s NMPA approves initiation of InnoCare’s trial of B7-H3 targeted ADCIn February 2025, the NMPA approved a Phase III trial of InnoCare Pharma’s ICP-248 (Mesutoclax) with orelabrutinib as a first ...
The market for B7-H3 inhibitors is expected to grow significantly in the coming years. This is due to the rising investment from leading pharma companies such as GSK, Merck, and others, the ...
4d
News Medical on MSNMost patients with advanced melanoma who received pre-surgical immunotherapy remain alive and disease free four years laterFour years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87 ...
The status has been given to the B7-H3-targeted drug as a treatment for late-line relapsed or refractory osteosarcoma, a rare form of bone cancer with no FDA-approved treatments.
BriaPro is developing novel antibodies to B7-H3, a key cancer antigen and immune checkpoint; Highly expressed on the cell surfaces of both tumor and immune cells, B7-H3 is a promising anti-cancer ...
11d
News-Medical.Net on MSNStudy unveils powerful strategy to rejuvenate effectiveness of CAR T cell therapy against glioblastomaA team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and ...
This FDA designation was based on the promising overall survival benefit in patients with brain tumors treated with an autologous B7-H3 CAR T-cell therapy observed in the BrainChild-03 Phase 1 ...
A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and ...
BriaPro is developing novel antibodies to B7-H3, a key cancer antigen and immune checkpoint; Highly expressed on the cell surfaces of both tumor and immune cells, B7-H3 is a promising anti-cancer ...
BriaPro is developing novel antibodies to B7-H3, a key cancer antigen and immune checkpoint Highly expressed on the cell surfaces of both tumor and immune cells, B7-H3 is a promising anti-cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results